{
  "title": "Esketamine: Postmarketing Safety Concerns",
  "itunes:title": "Esketamine: Postmarketing Safety Concerns",
  "pubDate": "Sat, 09 Oct 2021 16:00:00 +0000",
  "guid": "1b2ce3a8-591d-4b2e-be85-148581746102",
  "link": "https://psychopharmacology.libsyn.com/esketamine-postmarketing-safety-concerns",
  "itunes:image": "",
  "description": "<p>How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.</p> <p>Faculty: Jim Phelps, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115\"> <strong>Learn more about our memberships here</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115\"> <strong>Earn 0.5 CMEs: Quick Take Vol. 27</strong></a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/postmarketing-safety-concerns-with-esketamine-a-disproportionality-analysis-of-spontaneous-reports-submitted-to-the-fda-adverse-event-reporting-system-2591-5046?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115\"> <strong>Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System</strong></a></li> </ul> <p> </p>",
  "content:encoded": "<p>How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.</p> <p>Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= \"https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115\"> Learn more about our memberships here</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/publication/quick-take-vol-27-2591?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115\"> Earn 0.5 CMEs: Quick Take Vol. 27</a></li> <li><a href= \"https://psychopharmacologyinstitute.com/section/postmarketing-safety-concerns-with-esketamine-a-disproportionality-analysis-of-spontaneous-reports-submitted-to-the-fda-adverse-event-reporting-system-2591-5046?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC115\"> Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System</a></li> </ul> <p> </p>",
  "enclosure": "",
  "itunes:duration": "09:41",
  "itunes:explicit": false,
  "itunes:keywords": "",
  "itunes:subtitle": "How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.       ",
  "itunes:episodeType": "full"
}